In a dramatic shift in corporate strategy, Elliott Investment Management LP has relinquished an earlier pact with BioMarin Pharmaceutical Inc., nullifying an ongoing lawsuit and sidestepping a potential board upheaval. The initial agreement had granted the activist investor three additional seats on the board of the biopharmaceutical titan, sparking a legal battle that has now fizzled out in Delaware's courts.

Elliott Waives BioMarin Board Deal : Courtroom Conclusions

The legal drama reached a turning point late Tuesday when Vice Chancellor J. Travis Laster of the Delaware Chancery Court signed a six-page order. This order declared the lawsuit moot, following a mutual stipulation to dismiss by the involved parties. The now-dismissed class action was initially launched on April 4 by BioMarin shareholder Aaron Jones.

Elliott Waives BioMarin Board Deal : The Seeds of Dispute

The dispute originated when BioMarin's board agreed to a cooperation deal with Elliott in December, apparently to dodge a looming proxy fight. This deal, now defunct, would have expanded BioMarin’s board to include three Elliott-nominated directors—Mark Enyedy, Athena Countouriotis, and Barbara Bodem—in its 2024 electoral slate. In return, Elliott had promised to support the existing board and refrain from disparaging remarks under a standstill agreement.

Jones had challenged the validity of the agreement, particularly criticizing its clauses that limited board expansion and mandated shareholder endorsement for Elliott’s nominees. He deemed these provisions unenforceable, prompting his legal challenge.

Further Developments and Legal Maneuvers

In a proactive move, BioMarin’s board had already nominated the trio—Bodem, Countouriotis, and Enyedy—for the upcoming annual meeting, as disclosed in recent filings with the U.S. Securities and Exchange Commission. However, the lawsuit took a definitive turn on April 11 when Elliott officially waived the contentious parts of the agreement, according to documentation linked to the court’s decision.

Company Profile and Representation

Founded in 1997 and based in San Rafael, California, BioMarin stands as a global leader in biotechnology, focusing on therapies for rare genetic disorders. The company's legal representation includes Blake Rohrbacher from Richards Layton & Finger PA and Marjorie P. Duffy from Jones Day.

On the other side, Elliott's legal team comprises Andrew J. Rossman, Michael A. Barlow, and Hayden J. Driscoll from Quinn Emanuel Urquhart & Sullivan LLP. Representing Jones are Kurt M. Heyman and Aaron M. Nelson of Heyman Enerio Gattuso & Hirzel LLP, alongside Amanda Crawford and Joel Fleming from Equity Litigation Group LLP, and Richard A. Maniskas from RM Law PC.

As of the latest updates, none of the parties have publicly commented on the resolution of the lawsuit.